Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linrodostat - Bristol-Myers Squibb

Next Previous
Drug Profile

Linrodostat - Bristol-Myers Squibb

Alternative Names: BMS-986205; BMS-986205-04; F00-1287; Linrodostat mesylate; ONO-7701

Latest Information Update: 20 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Ono Pharmaceutical
  • Class Acetamides; Aniline compounds; Antineoplastics; Cyclohexanes; Quinolines; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bladder cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 19 Feb 2025 Bristol-Myers Squibb completes phase-I/II clinical trials in Solid tumours (Combination therapy,Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, Switzerland, Australia, France, Italy, Spain and USA (PO) (NCT03459222) (EudraCT2018-000058)
  • 29 Jul 2024 Thomas Jefferson University and Bristol-Myers Squibb terminates a phase II trial for Head and neck cancer (Combination therapy, First-line therapy, Metastatic disease) in USA due to toxicity - per sponsor (PO) (NCT03854032)
  • 28 Jun 2024 Discontinued - Phase-I for Glioblastoma (Late-stage disease, Newly diagnosed) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top